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Summary 
Primary brain tumours (gliomas) initiate a strong host response and can contain large 
amounts of immune cells (myeloid cells) like microglia and tumour infiltrating 
macrophages. In gliomas the course of pathology is not only controlled by the genetic 
make-up of the tumour cells, but also depends on the interplay with myeloid cells in the 
tumour microenvironment. Especially malignant gliomas like glioblastoma multiforme 
(GBM) are notoriously immune-suppressive and it is now evident that GBM cells 
manipulate myeloid cells to support tumour expansion. The pro-tumourigenic effects of 
glioma-associated myeloid cells comprise a support for angiogenesis as well as tumour 
cell-invasion, -proliferation and -survival. Different strategies for inhibiting the 
pathological functions of myeloid cells in gliomas are explored and blocking the tropism 
of microglia/macrophages to gliomas or manipulating the signal transduction pathways 
for immune cell activation have been successful in pre-clinical models. Hence, myeloid 
cells are now emerging as a promising target for new adjuvans therapies for gliomas. 
However, it is also becoming evident that some myeloid-directed glioma therapies may 
only be beneficial for distinct subclasses of gliomas and that a more cell-type specific 
manipulation of either microglia or macrophages may improve therapeutic outcome.  
2 
 
Neuropathological features of gliomas 
Glial tumours constitute approximately 50% of all newly diagnosed primary brain 
tumours, with low-grade gliomas accounting for roughly 15% of all brain tumours in 
adults [106]. The morphology and the cellular markers for gliomas share some 
similarities with the main macroglial cell-types (i.e. astrocytes, oligodendrocytes) [75]. 
Histopathologically, gliomas are divided into four different grades (according to the 
classification scheme by the world health organization, WHO), in which low-grade 
tumours are defined as grade-I/-II and high-grade gliomas as grade-III and-IV [87]. The 
presence of mitotic activity is a key feature for distinguishing low-grade from high-grade 
gliomas [75]. Statistically, low-grade astrocytomas arise roughly in proportion to the 
relative mass of the different lobes with most common location within the frontal lobes, 
followed by temporal and parietal lobe lesions [107]. Overall, 5- and 10-year survival 
rates of ~70% and 50% for grade-I and grade-II gliomas, respectively, have been reported 
in the literature [25]. The tumour tissue has no obvious signs of neoangiogenesis, 
infiltrative invasion or inflammation [75]. On the contrary, the outlook for patients with 
high-grade gliomas is grim. The majority of individuals diagnosed with a grade-IV 
glioma, which are very heterogeneous tumours and therefore also named glioblastoma 
multiforme (GBM), have a median progression-free survival of just over half a year and 
median overall survival of 15-18 months [17], only some subpopulations of patients show 
median survivals of almost 2 years [54]. GBM is a fast growing, highly angiogenic and 
invasive tumour and the diffuse growth is a major obstacle for GBM therapy. Other 
hallmarks of malignant gliomas are break-down of the blood-brain barrier (BBB), many 
hypoxic areas and necrotic centres [75]. Gliomas are usually diagnosed by neurorimaging 
(i.e. magnetic resonance imaging) and visualisation of the uptake of a contrast-enhancing 
agent within the tissue indicates BBB-leakage/breakdown [159]. GBM typically presents 
as a ragged contrast-enhanced and complex multi-cystic structure. GBM may be 
diagnosed de novo, i.e. in patients without a clinical history for brain tumours (then 
named primary GBM) or may evolve from lower grade gliomas (secondary GBM) [103].  
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Multi-modal glioma therapy 
Glioma therapy comprises very different strategies. For patients with deep-seated lesions 
or lesions located in eloquent regions which are clinically and radiographically indicated 
as low-grade glioma a conservative management including regular neuroimaging (after 
obtaining a histological diagnosis) [165], see also [130,150]. Individuals with high-grade 
gliomas undergo multi-modal treatment combining cytoreductive surgery, radiation- and 
chemotherapy (using a DNA alkylating agent, Temozolomide; TMZ) [106]. All in all, the 
approaches to treat high-grade gliomas are largely palliative and substantial efforts are 
made to improve prognosis and to define markers allowing a stratification of patients into 
therapeutically relevant phenotypes. Therefore, it was suggested to use gene expression 
profiling of the tumour mass, which can classify high-grade glioma according to different 
genetic subtypes (e.g. the proneural, classical or mesenchymal genotype) [19,152,113]. 
This GBM classification scheme may in the future help to dedicate more individualized 
and efficient therapies to patients.  
 
Accumulation of myeloid cells in gliomas 
Another striking feature especially of high-grade gliomas is the large number of immune 
cells, i.e. microglia and macrophages that accumulate in the tumour mass (tumour 
associated myeloid cells; TAM) [111,7,31]. Peripheral blood-derived macrophages are 
largely restricted to perivascular areas, the meninx and the choroid plexus in the tumour-
free brain, but accumulate in GBM after break-down of the BBB [123]. Microglia is 
abundant in the tumour-free CNS and comprises between 5% and 10% (depending on 
region) of all brain cells [71,83]; for comparison - the density of neurons is 
approximately 20% of cells in the human brain [57]. In GBM the number of TAM can be 
very high and constitutes up to 30% of the tumour mass [5,161,138,125], in 
medulloblastomas even 80% of all intra-tumoural cells can carry myeloid cell markers 
[138]. We observed that the distribution of TAM in GBM is very heterogeneous and the 
average number of these cells is between 20% and 30% (M. Synowitz and R. Glass, 
unpublished data). In most studies the quantification of TAM was performed in GBM 
samples (which is the most frequent intra-axial brain tumour) and TAM were reported to 
be less abundant in lower grade gliomas.  
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Microglia development 
Microglia and bone-marrow-derived monocytes/macrophages have largely overlapping 
marker profiles and to date there is no unequivocal method to distinguish both cell types 
in samples resected from human GBM [162]. This matter is not trivial since monocytes 
of the peripheral blood and microglia have different developmental origin and may have 
distinct function in physiology and pathology [129]. In contrast to monocyte-dendritic 
cell progenitors, microglial progenitor cells are generated in the yolk sac after gestational 
day 8.5, which is before the onset of definitive hematopoiesis (at E10.5, when monocytes 
arise) [44]. Both, microglia- and monocyte/macrophage-development depends on the 
myeloid master transcription factor PU.1 (also named spleen focus forming virus proviral 
integration oncogene, Spi-1) [73] and on the activity of the receptor for macrophage 
colony stimulating factor (CSF1R) [44], while the maintenance of microglial cells during 
adulthood depends on the activity of the tumour growth factor-β (TGF-β) receptor-1 [20]. 
Stimulation of CSF1R in microglia is mediated via macrophage colony stimulating factor 
(M-CSF) and interleukin 34 (IL34) [44]. This signal transduction pathway is not unique 
for the generation of microglia alone but is also essential for the generation of peripheral 
tissue-macrophages in the lung, liver (Kupffer cells) or skin (Langerhans cells) [129]. 
Generation of monocytes and macrophages during definitive hematopoiesis, in contrast to 
microglia, requires the transcription factor MYB1 and activation of the fms-related 
tyrosine kinase (FLT3, a cytokine receptor) [133]. After microglia precursors have 
entered the developing CNS (between E8.5 and E9.5) they differentiate into microglia 
and appear to self-renew in the brain throughout live [46]. Microglial cells do not need to 
be replenished from peripheral sources like the bone marrow [3], but previous 
experiments indicated that a transient ablation of all myeloid cells can lead to the 
colonisation of the brain with peripheral macrophages, which could then not be 
distinguished from bona fide microglia (in terms of morphology and with older sets of 
markers) [9]. Such experiments were interpreted to support the notion that monocyte-
derived macrophages and microglia largely share the same physiological role. However, 
today we observe that microglia also have unique roles in the CNS, which are different 
from classical functions of immune cells [109]. It was e.g. observed that microglia makes 
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close contact to pruning synapses and can participate in information processing of 
neurons [72].  
 
CNS Immunity 
The abundance of TAM in high grade gliomas has been initially been described more 
than 90 years ago [31] and over several decades researchers focused on delineating the 
inefficient immune-response of TAM [126,143,39]. It was concluded that the high levels 
of tumour growth factor-β (TGF-β) that are secreted from glioma cells have immune-
modulatory functions, which prevents myeloid cells from inducing a coordinated immune 
response against the tumour [68]. Indeed, it is now evident that TGF-β signalling is 
crucial for microglia in physiology and under neuropathological conditions [20]. 
However, only a sub-population of microglial cells may participate in controlling the 
adaptive immune response [49]. The current view is that peripheral macrophages and 
dendritic cells, in addition to microglia, can perform an important role for immune 
surveillance in the CNS [123]. Although the brain has no lymphatic vessels, which can 
transport antigen to deep cervical lymph nodes and to specialized dendritic cells, there are 
other routes by which peripheral immune cell can scan the immune status of the CNS. 
Peripheral macrophages can encounter antigen from the CNS, even with an intact BBB, 
by an exchange of interstitial brain fluids through the cribiform plate and through the 
choroid plexus into the periphery. Especially during auto-immune neuropathology it is 
evident that the peripheral immune system can mediate strong immunological action 
within the CNS. One promising way to exploit the peripheral control of CNS immune 
functions for brain tumour treatment is pursued by immunotherapy approaches [4]. Here 
e.g. cytokine application, serotherapy or active immunotherapy (to activate peripheral 
dendritic cells with antigen of tumour-origin) is used to prime the peripheral immune 
system to attack gliomas [55]. All in all, it is likely that re-activating antigen-presentation 
especially in bone-marrow derived immune cells (and additionally a relieve from 
immune-suppressive signals in tumour infiltrating lymphocytes, see below) would revive 
a functional anti-tumourigenic response of the adaptive immune system.  
 
 
6 
 
Distinguishing microglia from peripheral macrophages 
It was previously suggested that peripheral macrophages can be distinguished from 
microglia by means of CD11b and CD45 expression levels in the tumour-free mouse 
brain [58], in tumour models [7] and in human tumours [110]; while both cell types have 
high levels of CD11b on the plasma-membrane, only macrophages label intensely for 
CD45 and microglia have low CD45 levels. However, it is not clear how robust these 
markers really are in a glioma context; i.e. gliomas may modify the CD-molecule 
expression in TAM. To our experience, patient derived material often does not allow a 
distinction between the two cell-types based on CD-markers; most glioma biopsies 
harbour CD11bhigh/CD45high cells but biopsies containing CD11bhigh/CD45low populations 
are infrequent (M. Synowitz and R.Glass, unpublished observation). Peripheral and CNS 
immune cells were previously also distinguished by generating chimeric animals after 
sub-lethal irradiation and bone-marrow transplantation (e.g. from donors constitutively 
expressing green fluorescent protein; GFP) [117]. Microglia is radio-resistant and only 
the hematopoietic cells in the bone marrow are exchanged by this paradigm. This method 
requires that the brain is shielded from the radiation beam [94] since otherwise the BBB 
is opened and peripheral immune cells enter the CNS, populate some brain areas and 
generate tissue macrophages that share many microglial markers [32,169]. Anyway, the 
radiation procedure causes a massive release of cytokines into the circulation [134] that 
may also alter brain physiology. Recently, superior methods have been described to 
unequivocally separate microglia from peripheral immune cells. Genetic mouse models, 
which indicate developmental markers specifically for microglia or monocytes and 
monocyte-derived macrophages were generated and now distinct myeloid-cell 
populations can be observed without generating pathological side effects. It was reported 
that Flt3-cre induced recombination of an inducible reporter (flox-STOP-flox-YFP) very 
efficiently marks bone marrow-derived myeloid cells but spares microglia [133,46]. Also, 
a model was established to specifically indicate microglia using recombination (and 
activation) of an inducible reporter under control of the gene promoter for the fraktalkine 
receptor (Cx3cr1). Timed activation of Cx3cr1-CreErt2 by Tamoxifen application in 
transgenic animals crossed to a flox-STOP-flox reporter initially marks all myeloid cells, 
but the physiological turnover of peripheral monocytes and monocyte-derived 
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macrophage depletes reporter-positive immune cells from the peripheral blood while 
labelled microglia persists [45]. In another approach to distinguish microglia and blood-
borne myeloid cells, microglia was purified from physiological, blood-free brain samples 
and monocyte-derived macrophages were purified from peripheral blood, then direct 
RNA sequencing was used to identify differentially expressed genes in both cell-types 
[58]. Interestingly, it was found that certain purinergic receptors (like P2Y12) or surface 
molecules (like Siglec-H) are exclusive markers for microglia. Future work (e.g. using 
genetic recombination in transgenic models) will need to show if these differences persist 
in gliomas; if this is the case the it will be possible to therapeutically treat glioma-
associated microglia specifically (e.g. with purinergic compounds) or to identify 
microglia in glioma immunohistochemically. 
 
Microglial activation and innate immunity 
Classically, the immune cell function of microglia was observed after challenging the 
brain with bacterial pathogens (e.g. after sterile infection with lipopolysaccharides; LPS), 
these studies showed that microglia can undergo remarkable morphological changes [76] 
and become motile [1]. It was speculated that microglia revert from a “resting” state 
(associated with a stellate cell-shape) towards a motile and activated phenotype 
(associated with an amoeboid cell-shape) [121]. However, real-time observations by 
intravital microscopy revealed that microglia under physiological conditions are not 
immotile (as the term "resting" infers), but constantly scan the environment [121,30,100]. 
If lesions to the brain parenchyma are encountered, then microglial cells initiate a damage 
response, which can (depending on the extent of the lesion) also include other brain cells 
like astrocytes [50]. While the protection of the CNS from infection or injury is certainly 
a task for microglial cells, current studies also acknowledge the tissue protective role of 
microglia and show that these cells may contribute to neuronal survival in different 
neuropathologies [109]. Overall, it is established that microglia has a prominent role 
during acute inflammation. Here, pathogens activate microglia via stimulation of toll-like 
receptors (TLR), then microglia phagocytose [124] or kill microorganisms, by releasing 
reactive oxygen species (ROS)[69] or nitric oxide (NO) [35] and e.g. secrete 
inflammatory cytokines like tumour necrosis factor- α (TNF-α), interleukin-6 (IL-6), 
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IL10 and IL12 [62]. The physiological response of microglia to inflammatory pathogens 
is summarised as the M1-type of microglial activation [16]. Microglial cells also control 
the resolution of inflammatory events and participate in tissue repair functions including 
the induction of angiogenesis in lesioned areas [137,16]. During homeostasis the 
parenchymal cells, in particular neurons, present several plasma membrane molecules 
and release CX3CL1, which are recognised by microglia and prevent their activation 
[51,129]. The pro-inflammatory and tissue protective functions of microglia may also 
become apparent in gliomas but in a tumour environment they were, in most studies, not 
separated from the inflammatory reactions of monocyte-derived macrophages. Here, 
gliomas secrete IL4, IL6 and IL10 [139], as well as TGF-β [144] that induce an 
alternatively activated phenotype in TAM, which is referred to as M2-type of activation 
[78]. Increased production of prostaglandin E2 (PGE2) by glioma is associated with 
suppression of T-cell and TAM activation and plays an important role in the generation 
of an immunosuppressive environment [98].  The cell death pathway molecule FAS-
ligand (CD95-L or FASL) was found to be expressed by human GBM and both TAM and 
T-cells express the FASL receptor (FAS). It was recently reported that FASL contributes 
to local immunosuppression whereas there is no evidence that GBM-derived FASL 
induces TAM apoptosis [65]. TGF-β, macrophage-CSF (M-CSF), IL-4 and IL-10 
mediate an M2 phenotype of TAM. M2-activated TAM have e.g. reduced MHC-II levels 
[132], release IL10 [171,157], upregulate GM-CSF, IL-10, CXCL14 [42]  and vascular 
endothelial growth factor (VEGF) [101] and have increased expression of Arginase-1 
[37]. M-CSF expression in glioblastomas correlates with the expression of the M2 marker 
CD163 in TAM [78]. Both microglia and monocyte-derived macrophages share these M1 
and M2 features in neuropathology as well as in high-grade gliomas and the NF-ΚB and 
the signal transducer and activator of transcription-3 (STAT3) pathways have central 
roles in shifting TAM between M1 and M2 phenotypes [170,120,77]. Manipulation of the 
related signalling cascades may become a possibility to promote the anti-tumourigenic 
M1 type in TAM [59,2]. It should also be noted that a prototypical M1 phenotype (as 
initiated by LPS) or M2 polarisation (as observed during the resolution of inflammation) 
is usually not encountered in TAM [37,42]. It was observed that TAM in gliomas have an 
aberrant immune-type and share both M1 and M2 features (Fig. 1). Currently it is 
9 
 
unknown if myeloid cells homogenously have a mixed M1/M2 type or if there are 
distinct TAM subsets (subtypes of microglia as well as monocyte-derived macrophages) 
which are either more in the M1 or the M2 spectrum. Altogether, earlier work suggested 
that microglial cells were brain macrophages which can switch between “on” and “off” 
modes of activation – this image is now reverted and we see that microglia and 
monocyte-derived macrophages are assigned with an array of different brain-specific 
roles during physiology and pathology, which are not necessarily reflected by 
morphological changes.  
 
Adaptive immune functions in gliomas 
Systemic immunosuppression in patients with primary intracranial tumours has been well 
documented [163]. Deficits in the adaptive immune response of glioma patients are 
induced by tumour-released immune-modulatory cytokines [39,68] and partly by 
clinically applied corticosteroids (Dexamethasone) [8], which are given to reduce glioma-
associated edema [148]. Glioma patients have low peripheral lymphocyte counts, reduced 
delayed-type hypersensitivity reactions to recall antigen, impaired mitogen-induced 
blastogenic responses by peripheral mononuclear cells, and increased levels of CD8+ 
suppressor T-cells [81]. The lymphocyte deficit involves the T-helper (CD4+) subsets 
with decreased T-cell activity in vitro. Furthermore, there is diminished induction of 
immunoglobulin synthesis by B-cells in vitro from the peripheral blood of patients with 
intracranial tumour, probably related to diminished T-helper activity [14].  
Only activated T-cells can traverse the BBB and gain entry to the brain [123]. Then, brain 
infiltrating CD4+ T-cells may lose the activated status through the action of TGF-β 
released from glioma cells or TAM [151], or from TAM secreting IL-10 and C-C 
chemokine ligand-17 (CCL17), CCL18 or CCL22 [162]. Cytokines like TGF-β have 
been shown to suppress the production of both IL-1 and human leukocyte antigen (HLA) 
class-II molecules by antigen-presenting cells, and also suppresses the activation and 
proliferation of cytotoxic T lymphocyte (CTL) [64]. In GBM patients, systemic immune 
responses are unable to overcome the immunosuppressive tumour microenvironment and 
patients have reduced T-cell responses due to a number of factors including impaired T-
cell receptor (TCR) signalling, immunosuppressive cytokines, T-cell anergy (mediated by 
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regulatory T-cells, Treg, induced immune suppression), and dysfunctional antigen-
presenting cells [97,142]. Another study on GBM has shown that TAM had surface HLA 
class-II expression but lacked expression of the co-stimulatory molecules CD80, CD86, 
and CD40 critical for T-cell activation and thus were unable to activate T-cells [60]. 
Also, in GBM, there is a lack of effector and/or activated CTL and a relative abundance 
of Tregs [158]. One important aspect is a dramatic reduction in the expression of HLA 
molecules on the surface of tumour cells [67], which weakens their detection by CTL.  
Differential activation of STAT3 in TAM can control multiple immunosuppressive 
pathways in high-grade gliomas [162]. STAT3 activation in TAM is induced by different 
cytokines of the tumour microenvironment such as IL-10, IL-6, epidermal growth factor 
(EGF) and fibroblast growth factor. Activated STAT3 is known to reduce the expression 
of surface molecules necessary for antigen presentation such as MHC-II, CD80, and 
CD86 [79], as well as to increase the expression of many M2-specific 
immunomodulatory mediators including IL-10, EGF, VEGF, and various matrix 
metalloproteinsases (MMPs) [18]. It is currently unclear whether a single dominant 
molecule or a complex network of molecules is responsible for the immunosuppressive 
phenotype of glioma TAM, but STAT3 activation appears to play a key role in generating 
and perpetuating the M2-shifted TAM in gliomas.  
 
The pro-invasive function of myeloid cells in gliomas 
A specific role for microglial cells in brain tumours was addressed two decades ago 
[47,143]. Initially, in vitro studies showed that microglia, which can be purified from the 
fetal mouse or from the rat brain and maintained for limited times in cell culture, has 
profound effects especially on the invasiveness of glioma cells [95,6]. A seminal studies 
using Boyden chamber migration assays demonstrated that the presence of microglia 
facilitates the transmigration of glioma cells through a matrix containing barrier [11]. 
Especially the use of cultivated brain slices, which assures the preservation of original 
three-dimensional cellular context of the brain in an in vitro setting, has advanced our 
understanding of the specific role of microglia in gliomas [104,91]. Glioma cells, stably 
expressing a fluorescent reporter protein, can be inoculated into brain slices and the 
motility of the tumour cells can be monitored in real-time under conditions closely 
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resembling the in vivo situation. These slice cultures are a method of choice when a 
pharmacological treatments are investigated, since compounds that otherwise do not 
traverse the blood brain barrier can be applied into the tumour area. Furthermore, 
microglia can maintain their normal surveillance-function function scanning the brain for 
potential lesions (see above) and the role of microglial cells in gliomas can be 
investigated without the intratumoural accumulation of monocyte-derived macrophages. 
Techniques have been developed to specifically ablate microglia in brain slices without 
deteriorating the entire cellular architecture of such slice preparations. In tumour-
inoculated brain slice preparations the application of Clodronate-filled liposomes was 
instrumental to uncover important pro-pathological action of tumour-associated 
microglial cells [91].  The liposomes are rapidly and specifically taken-up by the 
phagocytic microglia and the payload (Clodronate) induces cytotoxicity. The dying 
microglia initially promotes astrocyte activation, which ceases after a relatively short 
interval (of three days). As a control, brain slices can be replenished (after Clodronate 
application) with exogenously cultivated microglia and the pro-tumourigenic effects are 
re-installed [91]. The course of tumour progression in microglia-containing versus 
microglia–depleted slices can be compared in this model. These experiments 
corroborated that microglia indeed has a pro-invasive effect in gliomas – as postulated 
from earlier cell culture studies. Conditioned media from the (glioma containing) brain 
slices had increased metalloprotease-2 (MMP2) activity only when microglia was present 
and then individual glioma cells invaded deeper into the brain tumour parenchyma. 
Importantly, this study showed that microglia promotes the activity of MMP2, but does 
not alter the expression levels of this enzyme. Metalloproteases are synthesised and 
secreted as inactive pro-forms and only the proteolytic cleavage of a peptide moiety 
converts the pro-enzyme into its active form [135] Then the active MMP2 can degrade 
extracellular matrix and facilitate glioma invasion. Subsequent studies with different 
mouse models supported these in vitro findings [93,154,92]. Ablation of myeloid cells by 
intra-tumoural application (via osmotic mini-pumps) of Ganciclovir in glioma-bearing 
animals engineered to express the herpes simplex thymidine kinase (HSVTK) gene, 
which converts of the pro-drug Ganciclovir into an active cell-death inducing agent, 
under a promoter for CD11b (Cd11b-Hsvtk) drastically diminished TAM numbers in 
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gliomas and largely reduced glioma size [92]. The molecular signalling pathway 
responsible for the glioma-supporting effect of TAM was uncovered and manipulated in 
another in vivo model. Here, we (and subsequently others) found that glioma cells release 
a (still unknown) soluble factor that triggers toll-like receptor-2 (TLR2)[154], which 
promote the activity of mitogen activated kinase (MAPK) p38 and of the TLR signal 
transducer MYD88 [92] in TAM. The MYD88 molecule induces the expression of 
another metalloprotease named membrane type-1 metalloprotease (MT1-MMP) on the 
plasma membrane of TAM. TAM-expressed MT1-MMP converts pro-MMP2 into active-
MMP2 thereby facilitating glioma motility (Fig. 2).  
The extracellular matrix in the brain has a different biochemical composition and 
architecture as compared to peripheral tissues like e.g. epithelia [99,33,127]. In epithelial 
tumours matrix-degradation and disruption of the epithelial layering is a hallmark for 
tumour progression and malignancy [99]. In the brain extracellular matrix components 
are less abundant and the matrix is heterogeneous between areas of grey and white 
matter, basement membranes are predominantly found along the vasculature, the 
meninges and parenchyma bordering with the ventricles [127]. Metalloproteinase-
mediated matrix degradation is therefore associated with different pathological effects as 
compared to epithelia and can result in increased invasion of glioma cells along the 
vasculature or also opening of the blood brain barrier [153,10,61]. MMP-activity has also 
signalling effects and can unmask cryptic amino-acid residues in the matrix[108,155], 
which stimulate growth factor receptors or bind to different integrins on tumour cells and 
can thereby support tumour expansion [149]. 
 
The pro-angiogenic role of myeloid cells in gliomas 
Another major role for MMPs on TAM is to initiate and to support the formation of new 
intra-tumoural blood vessels. The activity of MT1-MMP in concert with MMP2 disrupts 
basement membranes on blood-vessels and allows endothelial cell sprouting [149]. 
Additionally, TAM prime endothelial cells to sproute as they synthesize and release 
TNF-α and also other angiogenic molecules which have direct angiogenic effects or 
promote the secretion of vascular endothelial growth factor from glioma cells [140,101] 
(Fig. 3). The sprouting endothelia in gliomas need to be coordinated to form functional 
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vessels and especially the microglial cells may control this step, too. During development 
microglia localizes to vessel branch points, guides the endothelial tip-cells towards each 
other, induces tip- to stalk-cell conversion in the endothelia and thereby assures the 
building of functional vascular tubes [147]. TAM also express the pro-angiogenic MMP-
9 [63] or induce the expression of MMP-9 in glioma (stem) cells [167]. MMP-9 
participates in modifying the basement membrane and liberates growth factors like stem 
cell factor (SCF) [82] that acts as a specific agonist for the tyrosine kinase KIT. The KIT 
signalling pathway can recruit bone marrow-derived endothelial precursors to tumours 
and thereby augment the formation of vascular structures by a mechanism termed 
vasculogenesis [146]. However, another study suggested that vasculogenesis has only a 
minor role in GBM and that vascular sprouting and vessel cooption are the main drivers 
for the formation of new blood vessels in gliomas  [89].  It is likely that microglial cells 
have a specific role in the initial steps of intratumoural vascularization (when the BBB is 
intact and macrophages have not yet invaded the brain), subsequently the sprouting 
endothelia and later the monocyte-derived macrophages, which invade into the tumour, 
will also release pro-angiogenic signalling molecules and perpetuate the formation of 
vascular structures in gliomas.  As described above, anti-angiogenesis was regarded as a 
promising therapeutic strategy [102], but application of the VEGF-A-blocker 
Bevacizumab has clinically failed [90]. It is currently a matter of intense investigation if 
TAM can mediate resistance to Bevacizumab by releasing angiogenic factors 
alternatively to VEGF-A. Myeloid cells accumulating in GBM can promote the 
acquisition of a mesenchymal tumour-subtype [84,38,34], which is associated with 
resistance to Bevacizumab [114,115]. However, as with most pathways controlled by 
TAM, support of angiogenesis is only one side of the intra-tumoural actions of these 
immune cells in gliomas. Myeloid cells also inhibit intra-tumoural vessel formation e.g. 
by liberating angiostatins from the extracellular matrix, by activity of the urokinase type 
plasminogen activator [74]. In brain tumours the net effect of TAM pro- and anti-
tumourigenic activity is on the tumour supporting side, but there may be a possibility to 
shift this balance and promote the anti-tumour effects of glioma associated microglia or 
of  blood-borne macrophages that invaded into primary brain tumours.     
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Adenosine-5-triphosphate (ATP) was shown to stimulate the production of chemokines 
and CCl2 (MCP-1) and interleukin-8 (IL-8) in gliomas [66]. Nucleosides like adenosine 
modulate in an auto- and paracrine fashion the fine-tuning of the tumour-stroma-
interaction [15]. Extracellular adenosine itself is not only a passive product of tumour 
induced ischemia, hypoxia and necrosis but also actively released due to altered purine 
metabolism [85]. Most of the signalling actions of extracellular adenosine are mediated 
by G-protein-coupled cell-surface receptors that are divided into four subtypes: A1, A2A, 
A2B and A3 [40]. Adenosine has several inhibitory effects on M1 macrophage activation 
which are mediated by A2A receptors [53] and increases M2 macrophage activation [28]. 
VEGF production by macrophages is stimulated through A2A receptors and therefore it 
can support angiogenesis [122]. Microglial cells express functional A1A receptors and in 
gliomas selective stimulation of A1A inhibits the TAM activation [88,145]. 
 
Blocking the tumour supporting phenotype of myeloid cells 
While the abundant expression and release of TGF-β in gliomas was initially attributed 
only to the tumour cells, it now established that myeloid cells also generate TGF-β and 
thereby mediate important pathological effects [164,68,166]. In addition to blunting 
adaptive immune responses TGF-β was also observed to have direct effects on the highly 
aggressive subset of stem-like glioma cells especially in tumours of the mesenchymal 
genotype [112]. Application of Amphotericin-B can induce a tumour stem cell 
suppressive phenotype in TAM and mediates profound therapeutic effects in mouse 
models [131]. 
Of note, the ablation of myeloid cells in a mouse glioma model (using Cd11b-Hsvtk 
transgenic animals; see above) has also shown anti-tumour effects of TAM, previously. 
Here, systemic application of Ganciclovir was used which may have preferentially 
reduced the number of monocytes in the peripheral blood and monocyte-derived 
macrophages (which accumulate in gliomas) and under these settings an anti-
tumourigenic role for myeloid cells in gliomas was observed [43]. The anti-tumourigenic 
function of the macrophage population was addressed to their antigen-presenting capacity 
and to their ability to activate T-lymphocytes. Again, these results suggest that TAM 
have the capacity to mediate both pro- and anti-tumour effects and that it will be 
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interesting to dissect the function of intra-tumoural monocyte-derived macrophages or 
microglia in order to establish cell-type specific targets for adjuvans therapies for 
gliomas. 
The Flt3-cre [46] and Cx3cr1-CreErt2 [45] based models, in addition to newly 
established cell-surface markers [58], will advance our understanding of the cell-specific 
traits of microglia- or monocyte-derived macrophages in gliomas. Nevertheless, it is 
likely an oversimplification to regard either immune-cell population as homogenous 
[119]. There is solid evidence that microglia are heterogenic with respect to different 
brain areas and that they also undergo changes during aging [52]. These differences may 
not cause too much variance in experimental glioma models where tumour localisation, 
timing of tumourigenesis and genetic background of gliomas can be tightly controlled 
[23]. However, when analysing patient-biopsies heterogeneity is an issue since gliomas 
are located to different brain areas, patient-age can differ by several decades and gliomas 
are caused by a range of genetic mutations with consequences for cell-signalling and 
immunogenicity [87,103]. One way of patient stratification is to obtain glioma samples 
and to investigate the gene expression pattern assigning tumours to distinct genetic 
subclasses [19,152]. Preclinical glioma models indicated that this approach is important 
to identify individuals that may respond to myeloid-directed brain tumour therapies 
[118,12]. Blockade of CSFR1 signalling specifically in TAM by a small molecule 
inhibitor (BLZ945) had very robust anti-tumourigenic effects in a mouse glioma model 
resembling the proneural GBM-type [118]. Importantly, BLZ945 largely abrogated the 
tumour supporting function of TAM in a mouse model and the beneficial effects of 
CSFR1-inhibition were associated with the induction of a gene-expression signature that 
also served to predict improved survival in human GBM of the proneural subtype but not 
in other GBM subtypes. Another CSFR1 inhibitor (PLX3397) inhibited glioma cell 
invasion in an orthotopic implantation model using immune-competent mice [26]. 
However, in our hands CSF1R-inhibition did not mediate any anti-tumour effects, when 
using a related glioma mouse model (M. Synowitz and R. Glass, unpublished 
observations); suggesting that subtle differences in experimental procedures may have 
profound impact, when investigating TAM. Several studies suggest that inter-individual 
differences between gliomas, in particular the genetic subtype of tumours, can be of 
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importance to predict the outcome of immune-cell targeting therapies [84,38,34]. This is 
not surprising since the genetic subtype is determined from the entire tumour biopsy, 
which includes TAM. During progression and relapse GBM can convert from the 
proneural to the mesenchymal type [13,21,27] and it was shown that TNF-α release form 
intra-tumoural myeloid cells and TNF-α induced NF-kappa-B signalling in stem-like 
glioma cells can promote the conversion of the GBM genotype [12]. The shift from the 
proneural towards the mesenchymal glioma phenotype can promote radiation resistance 
in a subset of the proneural tumours. This has profound therapeutic implications, as NF-
ΚB blockade may be an important strategy to improve the outcome of radiotherapy. 
Altogether, the studies on the tumour-modulating effects of TAM in gliomas show that 
the expression signature has some predictive value for the application of e.g. BLZ945, 
but also indicate that the proneural subtype is not homogenous and that some proneural 
gliomas are sensitive to a TAM-induced mesenchymal drift. Hence, a better 
understanding of the gene expression pattern of TAM in glioma is necessary to e.g. 
stratify patients according to new myeloid cell-targeting adjuvans treatments that 
comprise CSFR1-inhibition or NF-ΚB blockade plus irradiation. The molecular analysis 
of tumour biopsies and different glioma cell subsets has largely advanced our 
understanding of the pathological processes in malignant brain tumours. Similar 
techniques have already been used in several pioneering studies to uncover prognostic 
markers and signalling pathways of myeloid cells in gliomas or neuropathological 
disease. With more studies on the genetic make-up of microglia and monocytes-derived 
macrophages in glioma mouse models we will obtain a more detailed picture on the 
potential therapeutic targets in subsets of TAM. The larger challenge ahead is to obtain 
similar data on TAM in human brain tumours, where we do not have easy access to 
relevant control samples from the tumour-free human brain (so different controls form 
post-mortem material and epilepsy surgery will be necessary) and where it will be 
difficult to prove if the markers distinguishing microglia and blood-borne macrophages in 
the mouse brain also apply to human cells. 
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The tropism of myeloid cells to gliomas 
In the past, additional TAM targeting strategies in preclinical glioma models also had 
beneficial effects. Application of the clinically approved immune-suppressive drug 
cyclosporine-A could strongly inhibit the pro-tumourigenic effects of myeloid cells in 
glioma [96,141,24]. Other investigator used stimulation of TLRs in glioma cells and in 
TAM as a therapeutic paradigm [48,36,70]. Another way to interfere with the tumour 
promoting role of myeloid cells in gliomas is to blunt the intra-tumoural accumulation of 
these immune cells by blocking chemoattractive signalling.  Experiments using 
encapsulated glioma cells showed that glioma-released soluble factors have major role in 
guiding myeloid cells towards the tumour mass. Here, glial-derived neurotrophic factor 
(GDNF) predominated chemoattraction of microglia in vitro, GDNF induced a tropism 
for myleoid cells towards gliomas in vivo and GDNF-knockdown in gliomas had a 
therapeutic function [80]. Other studies showed that CCL2 (MCP-1), CCL5, CCL7, 
VEGF-A [116,105,168] or (in hypoxic areas) stromal derived factor-1 [160] have 
prominent tropic function for myeloid cells in gliomas (Fig. 2). In contrast to the function 
of CX3CR1 in physiology, which promotes a resting state in microglia  [51], the same 
receptor can promote myeloid cell recruitment to human brain tumours and thereby 
support tumour expansion [56], but had no pathological role in a mouse model [86]. A 
recent publication suggests hypoxia-induced Semaphorin 3A (Sema3A) as a potent 
attractant for TAM by triggering VEGF-receptor-1 phosphorylation through the 
associated holoreceptor, composed of Neuropilin-1 (NRP1) and PlexinA1/PlexinA4. 
Importantly, whereas NRP1 levels are down-regulated in the hypoxic environment, 
Sema3A continues to regulate TAM in an NRP1-independent manner by eliciting 
PlexinA1/PlexinA4-mediated stop signals, which retain them inside the hypoxic niche 
[22]. Again, it is presently not known if these many different chemotropic molecules are 
active either in different glioma subtypes, or glioma models of distinct genetic 
backgrounds, if all myeloid cells respond equally to these pro-migratory cues or if there 
are distinct immune cell-subtypes which have a preference for the one or the other 
chemoattractive signalling pathway.   
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Future directions 
To date most studies on myeloid cells in glioma have uncovered specific pro- or anti-
tumourigenic function of myeloid cells in the untreated tumour. Especially in pre-clinical 
models distinct roles of TAM in tumour-antigen presentation, promotion of glioma-
invasion or angiogenesis were described. These data were backed up with findings from 
human biopsies, with the caveat that humans usually are treated with Dexamethasone 
before surgical tumour resection. Some exciting data are also available on the impact of 
myeloid cells on glioma treatment using irradiation [12,128]. It was observed that 
myeloid cells can support glioma cell survival and prevent the accumulation of anti-
tumourigenic reactive oxygen after radiochemotherapy. The myeloid cells provide 
alternative metabolites to glioma cells (quinilonic acid instead of NADH), which prevent 
the generation of reactive oxygen species that mediate some of the beneficial effects of 
radiochemotherapy [128]. Also it was shown that the composition of myeloid cell-
subtypes is altered throughout radiochemotherapy, with as yet unknown consequences for 
the therapy of glioma relapse [136]. One important topic that has not received much 
attention so far is the role of microglia during tumour formation and progression form 
low-grade to high-grade stages. It is postulated that gliomas arise from neoplastic 
transformation of stem and precursor cells (NPCs) in the brain or from de-differentiating 
astrocytes [23,41]. Microglia has been proven to be of importance for the turnover of 
NPCs [29,156] and it remains to be shown if microglia (e.g. during brain inflammation) 
contributes to the acquisition of somatic mutations in pre-neoplastic brain cells, which 
can drive tumourigenesis. Importantly, it was recently observed in a transgenic mouse 
model that CSFR1 blockade (by BLZ945) in myeloid cells can largely prevent/ slow-
down malignant progression of neoplastic brain cells into high-grade gliomas [118]. 
Given that there are often little treatment options for patients with low-grade gliomas it 
will be important to explore if tackling the glioma-associating microglia can prevent the 
malignant transformation of lower grade tumours. For basic science studies investigating 
the role of microglia in gliomas there is the advantage that lower-grade gliomas have an 
intact BBB, which implies that nor monocyte-derived macrophages have entered the 
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tumour area, and hence specifically the pathological impact of glioma-associated 
microglia can be studied in biopsies from human tumours.    
Altogether, we have now firm evidence that TAM are pathologically important and 
potential targets for adjuvans treatment of gliomas. Currently, we see an array of pro- and 
anti-tumourigenic effects of microglia or monocyte-derived macrophages, which make it 
difficult to directly translate immune cell-directed therapeutic approaches into clinical 
procedures. Uncovering the inter-individual heterogeneity of TAM in brain tumours and 
defining distinct pro- or anti-tumourigenic functions in microglia or blood-borne 
macrophages (and in subtypes of these cells) will help to set-up promising therapies and 
to locate patients that may profit from new TAM-targeting treatments.   
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Legends 
Figure 1. Myeloid cell polarization in glioma. Glioma-derived factors (black arrow) 
induce glioma-infiltrating myeloid cells (TAM) to adopt an immune-phenotype that is 
predominated by markers for the M2-type (alternatively activated), but M1-markers 
(classically activated) are also present. The M1-shifted TAM mediate anti-tumour effects 
(e.g. by initiating an adoptive immune response or by releasing cytotoxic oxygen- or 
nitrogen-radicals) whereas M2-shifted TAM drive tumour-growth, -invasion and 
angiogenesis (by releasing tumour cell-supporting cytokine, chemokines and angiogenic 
growth factors). M1- and M2-types are largely controlled by the signal transducer and 
activator of transcription (STAT) signalling pathways (STAT-1 and STAT-3) and can be 
induced in microglia and macrophages by different cytokines and growth-factors (blue 
arrows). Drugs like Amphotericin-B (Amph-B; a clinically approved anti-fungal agent), 
BLZ945 or PLX3397 (CSFR-1 inhibitors) are able to efficiently modulate glioma-
polarized myeloid cells; Amph-B can induce TAM activation (and TAM-mediated 
tumour stem cell suppression), while CSFR-1 inhibitors block acquisition of the M2 
phenotype in TAM.  
 
Figure 2. Glioma chemoattract myeloid cells and induce the a pro-invasive 
mechanism. Chemoattractants that have been shown to stimulate myeloid cell migration 
into the gliomas include CSF-1, GDNF, M-CSF and GM-CSF. An unidentified glioma-
released factor (?) stimulates toll-like receptor-2 (TLR2) in TAM and subsequently the 
p38-MAPK- and MYD88-pathway, then MT1-MMP is expressed and on the plasma-
membrane of TAM. MT1-MMP on TAM proteolytically cleaves glioma-derived pro-
MMP-2 (an inactive pro-enzyme), which is thereby converted into the active form 
(MMP2) that degrades the extracellular matrix (ECM) and promotes glioma invasion; 
matrix degradation can activate other TLRs in TAM and promote the accumulation of 
additional TAM.  
 
Figure 3. Mechanisms by which glioma-associated myeloid cells promote tumour 
angiogenesis. TAM have increased activity of MMPs (like e.g. MMP9) that  promotes 
the release of stem cell factor, which is a chemoattractive signal for bone marrow-derived 
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endothelial progenitors; thereby TAM potentially participate in vasculogenesis (1).  The 
chemokine CXCL12 induces the tropism of TAM to hypoxic areas that are not well 
vascularised or have aberrant vasculature (2), which may foster angiogenesis in these 
regions by the mechanisms describe in point-3. TAM activate ECM-modifying enzymes 
(MMPs) and release a variety of soluble factors (growth factors and cytokines) which 
have direct angiogenic effects (3).  
 



